Prof. Adam Elzagheid, MD, PhD, DOCENT - Biotechnology Research Center - Director General

Prof. Adam Elzagheid

MD, PhD, DOCENT

Biotechnology Research Center

Director General

Tripoli, Tripoli | Libyan Arab Jamahiriya

Main Specialties: Biotechnology, Pathology-Anatomic & Clinical

Additional Specialties: PATHOLOGY


Top Author

Prof. Adam Elzagheid, MD, PhD, DOCENT - Biotechnology Research Center - Director General

Prof. Adam Elzagheid

MD, PhD, DOCENT

Introduction

Dr. Adam Ibrahim Elzagheid
MD, PhD, Docent (Finland)
Professor of Pathology.
Genetic Engineering Department, Biotechnology Research
Centre, Tripoli, Libya.
Former Dean of Faculty of Medicine, University of Benghazi
Cell: 00218914461615
E-mail:elzagheid@btc.org.ly
elzagheid@yahoo.com

Dr. Adam Elzagheid is a professor at Biotechnology Research Centre (BTRC),
a General Director of BTRC, Tripoli, Libya.
Prior to his current job at BTRC, Dr. Elzagheid worked as a Dean of
Medicine, Benghazi University, Benghazi, Libya, Head of Department of Pathology,
Faculty of Medicine, University of Benghazi,
Associate at University of Turku, Faculty of Medicine, Oncology and Pathology
Departments, Turku, Finland.
Over the last twenty years at Turku University, Department of Pathology and
oncology (Turku, Finland), University of Benghazi, Department of Pathology
(Benghazi, Libya), (BTRC) Biotechnology Research Centre (Tripoli, Libya),
Elzagheid gained excellent teaching, research, administrative and managerial
experience, and this has been documented by interesting research paper.
? Research & development experience in the prognostication of tumor
biomarkers in solid tumors (such as; breast, c
tumors).
? Professional experience in curriculum development, articulations,
accreditation, professional certification, and Training.
? Teaching experience in general and systemic pathology, Research
Methodology, molecular pathology, Lab techniques.

For more information, please see the following links:
https://scholar.google.com/citations?user=EQQpGXAAAAAJ&hl=en
https://www.ncbi.nlm.nih.gov/pubmed/?term=Elzagheid+A
https://www.researchgate.net/profile/Adem_Elzagheid

Primary Affiliation: Biotechnology Research Center - Tripoli, Tripoli , Libyan Arab Jamahiriya

Specialties:

Additional Specialties:

Research Interests:


View Prof. Adam Elzagheid’s Resume / CV

Education

May 2013
University of Turku, Department of Pathology
Docent
Jan 2004
University of Turku, Faculty of Medicine, Department of Pathology
PhD
Dec 1996
University of Benghazi, Faculty of Medicine
MBChB

Experience

Dec 2018
Grant from Authority of Natural Science, Research and Technology, Tripoli, Libya

Publications

32Publications

294Reads

3Profile Views

107PubMed Central Citations

Expression of Lamin A/C in early-stage breast cancer and its prognostic value.

Breast Cancer Res Treat 2019 Apr 4;174(3):661-668. Epub 2019 Jan 4.

Division of Breast Surgery, The University of Nottingham, Nottingham, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-05092-wDOI Listing
April 2019
5 Reads
3.940 Impact Factor

Organ-on-a-Chip: New Tool for Personalized Medicine.

J Craniofac Surg 2018 06;29(4):823-824

Biotechnology Research Center, Authority for Natural Sciences Research and Technology, Tripoli, Libya.

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00001665-201806000-0000
Publisher Site
http://dx.doi.org/10.1097/SCS.0000000000004604DOI Listing
June 2018
6 Reads
0.680 Impact Factor

Poster abstracts of the 18th Pan Arab Cancer Congress. TUNISIA. April 19-21, 2018.

Authors:
J Aarab Ibtissem Abbess Fathi Abdalla Z Abdelaziz S Abdelfattah I Abdelli K Abdelmajid Zied Abdelsselem N Abdelwahed Nihed Abdessayed Bassem Abid K Abid R Abidi Asma Abudabbous Sana Abujanah Afaf Aburwais E Acacha Nessrine Acharfi Nejmeddine Affes R Aftis I Ahalli Mr Aid D Aissaoui A Alaoui M Alaoui Salaheddin Albatran Aldehmani Mamdouh Rabia Alkikkli A Allam S Aloulou Omar Alqawi Mussa A Alragig Ali Alsharksi K Oualla L Amaadour L Amaadour N Ameziane A Ammari H Ammour R Amrane N Annad E Aouati S Aouichat S Aouragh S Arifi Md Astra M Atassi Nidhal Ati K Atoui L Atreche S Ayachi I Ayadi Mohammed Ali Ayadi Mouna Ayadi Jihene Ayari Haroun Ayed K Ayed Henda Ayedi Ines Ayedi M Azegrar Heifa Azzouz Fathi Babdalla R Bachiri Z Bachiri M Baghdad R Bahloul A Bahouli M Bahri I Baississ Hanae Bakkali Mehdi Balti O Baraket Hayfa Bargaoui Rim Batti Ahlem Bedioui R Begag Z Behourah Imtinene Belaid Asma Belaïd Amine Ben Abdallah Ichrak Ben Abdallah Slim Ben Ahmed Tarek Ben Ahmed M Ben Azaiz M A Ben Chehida Leila Ben Fatma D Ben Ghachem T Ben Ghachem J Ben Hassouna S Ben Hmida Sonia Ben Nasr Dalel Ben Nejima K Ben Rahal M Ben Rejeb S Ben Rhouma I Ben Safta A Ben Salem Yosr Ben Zargouna Ichrak Benabdallah H Benabdella Mohamed Zied Benabdessalem Khaled Benahmed Slim Benahmed Hazem Benameur S Benasr Fz Benbrahim W Benbrahim Z Benbrahim Ma Benchehida Yasser Bencheikh Tarek Bendhiab Leila Benfatma A Bengueddach M Benhami Jamel Benhassouna W Benhbib Noureddine Benjaafar R Benkali Wala Benkridis A Benlaloui Mahmoud Benmaitig A Benmansour M Benmouhoub Farouk Benna H Benna Marouan Benna Mehdi Benna H Bennabdellah Khaled Benrahal Ines Bensafta Hanène Bensalah A Bensalem Mohammed Bensaud Riadh Benslama M Benyoub K Benzid H Bergaoui M Beroual S Berrad Y Berrazaga Z Bezzaz Hanene Bhiri M Bibi Mohamed Yassine Binous Ahlem Blel Jamela M Boder N Bouaouina Hanen Bouaziz S Bouchoucha Tahia Boudawara Zaher Boudawara A Bouderbala Rima Bouhali Malek Bouhani R Boujarnija Salah Boujelben Nadia Boujelbene I Boukerzaza H Boukhari W Boulfoul R Boulma N Boumansour A Bouned A Bounedjar I Bouraoui Saadia Bouraoui Rym Bourigua M Bourmech Hamza Bousaffa A Bousahba C Bousrih A Boussarsar Hammouda Boussen Selwa Boutayeb Khaled Bouzaidi Faten Bouzaiene H Bouzaiene Z Bouzerzour Kamel Bouzid N Bouzid Dw Bouzidi W Bouzidi Abderrazek Bouzouita S Brahimi A Brahmia Abdelbaset Buhmeida Kais Chaaben Hatem Chaabouni Mohamed Chaabouni Kais Chaabène H Chaari Ines Chaari M Chaari Imene Chabchoub K Chabeene K Chaker Marouene Chakroun M Charfi Slim Charfi R Chargui Md Charles Mohamed Chebil Khadidja Cheikchouk Beya Chelly Ines Chelly N Cheraiet Aziz Cherif Mohamed Cherif A Cherifi T Chikhrouhou A Chikouche A Chirouf Nesrine Chraiet Y Collan Zhanglin Cui Habiba Dabbebi Amira Daldoul I Damouche H Daoud N Daoud J Daoued Khadija Darif Dalia O Darwish Z Derbouz Amine Derouiche T T Dhibe Tarek Dhibet A Djallaoui N Djami K Djebbes H Djedi S Djeghim L Djellali A Djellaoui K Djilat R Djouabi H Doumbia Mustafa Drah M Dridi Mohamed Hsairi S Elabbassi Fz Elallia Zohra Elati M Elattassi Houda Elbenna Mohamed A Elfagieh Omran Elfaitori Hebatallah Elfannas Amine Elghali Mohamed Amine Elghali Salah Elgonti O Elamine Elhadj R Elhazzaz H Elkacemi Khaoula Elkinany Youssri Elkissi F Elloumi Olfa Elmaalel I S Elmajjaou S Elmajjaoui H Elmhabrech Fz Elmrabet Wesam A Elsaghayer Adam Elzagheid Fatma Emaetig H Erraichi Mejda Essid Nada Ewshah Faten Ezzairi Raja Faleh Sourour Fallah Amr Lotfy Farag L Farhat R Fehri Jihène Feki Sami Fendri Sana Fendri Z Fessi Taha Filali A Fissah M Fourati N Fourati Mounir Frikha C S Fuchs Azza Gabssi F Gachi Selma Gadria A Gammoudi I Ganzoui Asma Gargoura Imen Ghaddabb Imen Gharbi Maroua Gharbi E Ghazouani N Gheriani Abdelmonom Ghorbel L Ghorbel A Ghozi Rafik Ghrissi Amine Gouader A Goucha A Guebsi I Guellil Fatma Guermazi Sondess Guesmi Wafa Guetari N Habak A Haddad S Haddad Abderrazek Haddaoui I Hadef Abdelbasit Faraj Hader A Hadiji F Hadjarab Myriam Hadoussa Nadia Hadoussa Ch Hafsa Mariem Hafsia Ahmed Hajji M Hajmansour S Hamdi Z Hamici S Hamida Fehmi Hamila Selim Hamissa Boussen Hammouda Slim Haouet I Harhira Ayed Haroun K Hassouni A Hdiji Monia Hechiche L Hejjane C Hellal Manseurs Henni K Herbegue L Hichami M Hikem Alaa Hmad Lina Hmida S Hmissa Makrem Hochlaf A Houas M Houhani Ali Huwidi Chau Ian B N Ibrahim Noha Y Ibrahim H Idir Dhilel Issaoui A Itaimi A E Izem Olfa Jaidane Daoud Jamel H Jamous Medsalah Jarrar Mohamed Salah Jarrar Saber Jarray M Jebsi Hafedh Jmal Abdallah Juwid Ons Kaabia A Kablouti Imene Kacem K Kacem M Y Kaid M Kallel R Kallel H Kammoun Syrjänen Kari Sarra Karrit Hela Kchir Nidhameddine Kchir T Kebdani N Kechad H Kehili E Kerboua Hassib Keskes Nora N Kessi N Khababa H Khaldi Afef Khanfir B Khater A Khelif S Khemiri K Khennouf H Khouni S Khrouf Zahra Kmira L Kochbati Asma Korbi N Kouadri F Kouhen M Krarti M Handoussa Yanzhi Hsu Ons Laakom Matti Laato Soumaya Labidi Fz Lahlali A Lahmidi A Lalaoui Naija Lamia A Lamri Feryel Letaief M R Letaief M Aldehmani A Rafael A M Liepa Faten Limaiem K Limam H Loughlimi F Ltaief Nadia Maamouri Mohamed Mabrouk R Madouri N Mahjoub Z Mahjoubi M Mahrsi Hochlef Makrem W Mallek Moez Manitta L Mansoura Houyem Mansouri Maher Maoua W Maoui Chakroun Marouene K Marzouk S Masmoudi Fatma May I Meddeb Khedija Meddeb S Meddour Fatma Medhioub Nesrine Mejri Mohamed Rochdi Melizi N Mellas Rihab Melliti A Melzi N Merair F Z Merrouki C Mersali O Messalbi Lina Messaoudi S Messioud K Messoudi Sarra Mestiri Amal Mezlini Amel Mezlini F Mghirbi H Mhabrech A Mhiri N Midoun Rabia Milud B Missaoui Aymen Mnasser Wafa Mnejja Moncef Mokni Amina Mokrani Mokrani Mokrani R Moujahed Y Moukasse A Mouzount Karima Mrad Mohamed Hedi Mraidha Nejib Mrizak Rafik Mzali Y Mzid F M'ghirbi Abdelwaheb Nakhli Chiraz Nasr Salsabil Nasri Gef Noubigh Daoud Nouha L Nouia Y Nouira A Noureddine O Nouri Atsushi Ohtsu H Ouahbi K Oualla Y Ouanes H Ouaz A Ouikene N Ouldbessi Iqbal Parker S Pyrhonen H Rachdi K Rahal Khaled Rahal M Rahoui Henda Raies Soumaya Rameh K Reguieg Haitham Rejab R Rejiba Mohamed Salah Rhim S Riahi N Rouimel N Saad Saoud K Saadi Myriam Saadi A Sadou Ines Saguem T Sahnoun H Sahnoune Saida Sakhri A Sallemi Asma Sassi W Sbika C Sedkaoui S Sefiane A Sellami Pyrhönen Seppo H Sfaoua Syrine Sghaier Ali Shagan W Siala I Slim M Slimene S Soltani S Souilah Marwa Souissi Badreddine Sriha Badreddine Youssef Swaisi A Taibi T Taktak Ghofran Talbi S W Talha Soha M Talima S Tbessi N Tebani S Tebra S Tebramrad D Telaijia A Tenni Ahmedou Tolba Yassen Topov K Touil Nabil Toumi W Toumi N Tounsi Aymen Trigui R Trigui W Triki Maroua Walha Ines Werda Haythem Yacoub Yosra Yahyaoui A Yaich R Yaici M Yamouni I Yeddes D Yekrou Ma Yousfi N Yousfi M A Youssfi L Zaabar Sonia Zaied I Zaim Walid Zakhama S Zayed Alia Zehani I Zemni Yosr Zenzri S Zeraoula O Zouiten Olfa Zoukar Ws Zrafi Aref Zribi Naji Zubia

Tunis Med 2018 Apr;96(4):177-182

View Article

Download full-text PDF

Source
April 2018
27 Reads

Neurofibromin Expression is Associated with Aggressive Disease and Poor Outcome in Colorectal Carcinoma.

Anticancer Res 2016 10;36(10):5301-5306

Department of Oncology and Radiotherapy, Turku University Hospital and University of Turku, Turku, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.11102DOI Listing
October 2016
15 Reads
1 Citation
1.872 Impact Factor

High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer.

Anticancer Res 2013 Aug;33(8):3137-43

Department of Pathology, Faculty of Medicine, Benghazi University, Benghazi, Libya.

View Article

Download full-text PDF

Source
August 2013
14 Reads
10 Citations
1.872 Impact Factor

Loss of MUC2 expression predicts disease recurrence and poor outcome in colorectal carcinoma.

Tumour Biol 2013 Apr 21;34(2):621-8. Epub 2012 Nov 21.

Department of Pathology, Faculty of Medicine, Benghazi University, Benghazi, Libya.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13277-012-0588-8DOI Listing
April 2013
9 Reads
10 Citations
2.840 Impact Factor

Survivin Expression in Renal Cell Carcinoma and Its Correlation with Clinicopathological Parameters

J Interdiscipl Histopathol 013; 1(4): 184-194

Journal Interdisciplinary Histopathology

Abstract Objective: The aim of the current study is to cast further light on the issues related to prognostication of renal cell carcinoma (RCC), assessi ng the expression of survivin in a subset of primary RCC and determine its relation to di fferent clinicopathological features and disease free survival. Methods: The present series consisted of tissue sam ples obtained from 37 Libyan patients with stage I, II, III, or IV RCC. Survivin ex pression in these tumors was assessed by immunohistochemistry using an automated staining system. Different grading systems were tested for expression of survi vin. Results: Expression of survivin was significantly as sociated with venous invasion (tumor thrombus) (p= 0.042), larger tumor size (p= 0.051), higher primary T classification (p= 0.013), advanced tumor stage (p= 0.033), and borderline association (p= 0.068) with tumor location. In univariate (Kapl an-Meier) survival analysis, survivin expression showed a borderline association (p= 0.08 9) with disease-free survival (DFS). However, there was no significant correlation betwe en survivin expression and gender, age, histological grade, distance metastasis, lymph node involvement, perinephric fat and capsular invasion, status at end point and recu rrence. Conclusion: Survivin expression in RCC may identify pat ients at risk of a more aggressive disease and a worse prognosis, further i nvestigations, on a larger and more heterogeneous population, should be carried out to validate and extend our results.

View Article
March 2013
15 Reads

Over-expression of HER-2 is associated with the stage in carcinomas of the urinary bladder.

Libyan J Med 2012 8;7. Epub 2012 Mar 8.

Department of Pathology, Faculty of Medicine, Garyounis University, Benghazi, Libya.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3402/ljm.v7i0.14694DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3298183PMC
October 2012
8 Reads
3 Citations

Loss of E-cadherin expression predicts disease recurrence and shorter survival in colorectal carcinoma.

APMIS 2012 Jul 23;120(7):539-48. Epub 2012 Jan 23.

Department of Pathology, Garyounis University, Benghazi, Libya.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0463.2011.02863.xDOI Listing
July 2012
12 Reads
7 Citations
1.922 Impact Factor

Angiogenesis in urinary bladder carcinoma as defined by microvessel density (MVD) after immunohistochemical staining for Factor VIII and CD31.

Libyan J Med 2011 Mar 31;6. Epub 2011 Mar 31.

Department of Pathology, Faculty of Medicine, Garyounis University, Benghazi, Libya.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3402/ljm.v6i0.6016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081871PMC
March 2011
125 Reads
7 Citations

Image DNA cytometry in FNABs of Libyan breast disease

Anticancer Res. 2010 Jan;30(1):175-81.

Anticancer Research

BACKGROUND: The sensitivity for identification of malignant cells in conventional fine-needle aspiration biopsy (FNAB) investigation is about 80%. This percentage is dependent on the number of examined cells, type of breast cancer, and experience of the examiner. The aim of our study was to estimate the supporting value of image DNA cytometry of FNAB of the breast, and do so by using different sampling methods. MATERIALS AND METHODS: This retrospective study was based on 41 cases with an available histological diagnosis: 18 benign lesions and 23 malignant tumours were examined. The smears were submitted to image DNA analysis in a three-step protocol: (i) smears stained with HE method were destained and (ii) then restained with Feulgen staining for DNA and (iii) finally analysed using image cytometry. RESULTS: All non-malignant cases had diploid histogram. However, a few of them had one or two cells of >5c category. Most histologically malignant cases were aneuploid. Only three invasive ductal carcinomas showed diploid histograms. All samples with aneuploid histograms were malignant. CONCLUSION: The results confirm earlier published data in the Finnish population and indicate that image DNA cytometric analysis of nuclear content is a useful marker for identification of malignant cells in FNAB, especially after free cell sampling. The method can be used to increase the cytological sensitivity and specificity in doubtful breast lesions.

View Article
January 2010
8 Reads

The Potential Value of EGFR and P53 Immunostaining in Tumors of the Urinary Bladder.

Libyan J Med. 2009 Dec 1;4(4):143-5.

Libyan J Med

The expression of EGFR and p53 has not been adequately studied as a prognostic tool in urinary bladder tumors. We analyzed 74 bladder cancer samples from Egypt for EGFR and p53 expression using immunohistochemistry. The tumors were of different histological types, grades and clinical stages, and with established lymph node status. Almost 61% of the tumors showed positive membranous EGFR expression and 74.3% had positive nuclear staining of p53. Analysis of correlation of the IHC staining with clinical variables showed a significant correlation only between EGFR expression and histological type (p=0.002, ANOVA), in that the expression was higher in squamous cell carcinomas than in other histological types. There were no significant correlations between p53 or EGFR with the other clinicopathological variables, including age, sex, staging, grading, and lymph node status. Further studies are needed to determine if EGFR and p53 might be used as prognostic tools in bladder cancer.

View Article
December 2009
8 Reads

Mutations/polymorphisms in the 55 kDa subunit of DNA polymerase epsilon in human colorectal cancer.

Cancer Genomics Proteomics. 2009 Nov-Dec;6(6):297-304.

Cancer Genomics Proteomics.

BACKGROUND: Defects of some DNA polymerases have shown associations with cancer, but data on DNA polymerase epsilon are limited. This study investigated mutations in the 55 kDa subunit gene of DNA polymerase epsilon in colorectal cancer. MATERIALS AND METHODS: DNA from 16 human colorectal cancer and 9 control samples was studied with polymerase chain reaction-single-strand comformation polymorphism analysis and DNA sequencing. RESULTS: DNA polymerase epsilon gene alterations were identified in 5 out of the 16 cases (31.2%). Two samples showed a T-C transition at exon 17 (potential tyrosine to histidine substitution), and an A-G transition at intron 7; one sample showed an A-G transition at intron 8. An AATT deletion was observed at intron 18 in 3 out of the 16 colon cancer cases (grades 2, 3, and 2, and Dukes' classes C, D, and C, respectively). CONCLUSION: Because the AATT deletion has also been found in breast cancer, the region may be a mutation hot spot, possibly involved in the carcinogenetic path in advanced colorectal cancer.

View Article
November 2009
5 Reads

DNA image cytometry predicts disease outcome in stage II colorectal carcinoma.

Anticancer Res. 2009 Jan;29(1):99-106.

Anticancer Res

BACKGROUND: Approximately 30% of all colorectal cancer (CRC) patients are diagnosed with stage II disease. Adjuvant therapy is not widely recommended. However, it is well established that a subgroup of patients with stage II are at high risk for recurrence within their lifetime and should be considered for adjuvant chemotherapy. The present work was designed to study the prognostic value of nuclear DNA content in stage II CRC of patients with long-term followup. PATIENTS AND METHODS: Isolated nuclei from 50 microm-thick paraffin sections of tissue samples from 253 patients with stage II CRC, who had undergone bowel resection at Turku University Central Hospital were cytocentrifuged on slides, stained with Feulgen staining, and DNA was measured using a computer-assisted image analysis cytometry system. Different approaches were applied in analysis of DNA histograms. RESULTS: DNA content did not show any relation with age (p < 0.96), sex (p < 0.35), tumor invasion (p < 0.77), or grade (p < 0.31). Aneuploid DNA content was significantly more frequent in the cancer of the left colon and rectum than the right colon (p = 0.02). S-phase fraction analysis revealed that a higher proportion (62%) of the older patients (>65 years) had high proliferation rates than did the younger patients (p < 0.05). Patients with narrow range histograms had a better disease-free survival (DFS) (narrow range: 70%, wide range: 60% at 10 years). Tumors with >9c nuclei were associated with significantly better DFS and disease-specific survival (DSS) as compared with the patients who did not have >9c nuclei in their tumor samples (p < 0.003 and p < 0.0001, respectively). Multivariate survival (Cox) model showed that only classification of the basic pattern of the histogram [odds ratio OR) = 29.14; 95% confidence interval (CI) 2.350-361.57] (p = 0.009) and recurrence (OR = 165.35; 95% CI 48.42-564.7) (p = 0.0001) proved to be independent predictors of clinical outcome. CONCLUSION: Our results seem to suggest it truly is possible, by using DNA cytometry, to find groups with different prognosis among stage II cases. Those with a high recurrence rate should be considered for adjuvant chemotherapy.

View Article
January 2009
20 Reads

Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer.

Hum Pathol 2008 Dec 12;39(12):1737-43. Epub 2008 Aug 12.

Department of Oncology and Radiotherapy, Turku University Hospital, FIN-20521 Turku, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2008.04.020DOI Listing
December 2008
5 Reads
32 Citations
2.770 Impact Factor

Nuclear morphometry in FNABs of breast disease in Libyans.

Anticancer Res. 2008 Nov-Dec;28(6B):3985-9.

Anticancer Res.

BACKGROUND: Nuclear morphometry can be expected to improve the distinction between benign and malignant lesions. PATIENTS AND METHODS: Forty fine-needle aspiration biopsy (FNAB) samples fixed in 50% ethanol were collected at the African Oncology Institute, Sabratha, Libya, during the period 2004-2007. All diagnoses reported were confirmed histologically. There were 23 cases of infiltrating ductal carcinoma and 17 of benign breast disease. Two different assessment methods were applied: measurements made on cell groups, and those made on free cells. Apocrine metaplasia was excluded. Five different size parameters (include mean nuclear area, MNA) and 6 shape factors were measured. RESULTS: The size parameters showed significant differences between benign and malignant cases. The mean, median and 95% percentiles of nuclear area in both types of assessment were especially significant. The shape parameters were not significant. CONCLUSION: The study suggests that interactive computerized nuclear morphometry is an efficient and successful tool in distinguishing between cases of benign and malignant disease. Combination of our data with earlier free cell data gave the following diagnostic guidelines: Range of overlap in free cell samples: MNA 55 microm2 - 71 micro2. Cut-off values for diagnostic purposes: 100% detection of malignant cases: MNA > 54 microm2 (specificity 84%), 100% detection of benign cases: MNA < 72 microm2 (sensitivity 91%).

View Article
November 2008
13 Reads

Up-regulation of alpha-catenin is associated with increased lymph node involvement in colorectal cancer.

World J Gastroenterol 2008 Aug;14(31):4903-8

Department of Pathology, University of Turku, Kiinamyllynkatu 10, Turku, Finland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2739943PMC
http://dx.doi.org/10.3748/wjg.14.4903DOI Listing
August 2008
10 Reads
2 Citations
2.370 Impact Factor

Nuclear beta-catenin expression as a prognostic factor in advanced colorectal carcinoma.

World J Gastroenterol 2008 Jun;14(24):3866-71

Department of Pathology, University of Turku, Kiinamyllynkatu 10, FIN-20520, Turku, Finland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721444PMC
http://dx.doi.org/10.3748/wjg.14.3866DOI Listing
June 2008
8 Reads
17 Citations
2.370 Impact Factor

Expression of the cell-cell adhesion molecule beta-catenin in colorectal carcinomas and their metastases.

APMIS. 2008 Jan;116(1):1-9

APMIS

To study the dynamic events leading to impaired cell-cell adhesion upon transition to the invasive phenotype of colorectal cancer (CRC), we examined three distinct beta-catenin expression patterns (membranous, cytoplasmic, and nuclear) in the paired samples of the primary tumours (P) and their metastatic lesions (M). beta-catenin expression was detected by immunohistochemistry (IHC) in 33 pairs of the primary CRC and their metastases. In a pair-wise (P-M) comparison, the membranous index (MI) was significantly different between P and M (p=0.036, Wilcoxon Signed-Ranks test), while cytoplasmic index (CI) and nuclear index (NI) values did not significantly deviate between P and M. MI in primary tumours was inversely related to the patient's age (p=0.04) and tumour grade (p=0.03), while patients with low MI in M had a high rate of metastasis at diagnosis (p=0.06). CI in P was lower in patients with LN involvement (p=0.02) and in advanced tumour stage (p=0.002). Tumours of the ascending colon had the highest CI in their M (p=0.04). Interestingly, high MI of the M lesions was a significant predictor of favourable overall survival (OS) in univariate (Kaplan-Meier) survival analysis (p=0.035). In conclusion, significant aberrations in beta-catenin expression probably take place in CRC cells during the development of metastatic phenotype, but a change from membrane expression to cytoplamic and/or nuclear expression is not a prerequisite for metastasis in all cases.

View Article
January 2008
8 Reads

Thymidylate synthase expression in primary colorectal tumours is correlated with its expression in metastases.

Scand J Gastroenterol 2007 Apr;42(4):471-6

Department of Oncology and Radiotherapy, Turku University Hospital, Savitehtaankatu 1, P.B 52, FIN-20521 Turku, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00365520600960120DOI Listing
April 2007
15 Reads
2 Citations
2.330 Impact Factor

Lymph node status as a guide to selection of available prognostic markers in breast cancer: the clinical practice of the future?

Diagn Pathol. 2006 Nov 8;1:41.

Diagn Pathol

Prognosticators evaluating survival in breast cancer vary in significance in respect to lymph node status. Studies have shown e.g. that HER2/neu immunohistochemistry or HER2/neu gene amplification analysis do perform well as prognosticators in lymph node positive (LN +) patients but are less valuable in lymph node negative (LN -) patients. We collected data from different studies and tried to evaluate the relative significance of different prognosticators in LN+/LN- patient groups. In LN+ patients HER2/neu and E-cadherin immunohistochemistry were the statistically most significant prognosticators followed by proliferation associated features (mitotic counts by SMI (standardised mitotic index) or MAI (mitotic activity index), or S-phase fraction). Bcl-2 immunohistochemistry was also significant but p53 and cystatin A had no significance as prognosticators. In LN- patients proliferation associated prognosticators (SMI, MAI, Ki-67 index, PCNA immunohistochemistry, S-phase fraction) are especially valuable and also Cathepsin D, cystatin A, and p53 are significant, but HER2/neu or bcl-2, or E-cadherin less significant or without significance. We find that in studies evaluating single prognosticators one should distinguish between prognosticators suitable for LN+ and LN- patients. This will allow the choice of best prognosticators in evaluating the prospects of the patient. The distinction between LN+ and LN- patients in this respect may also be of special value in therapeutic decisions.

View Article
November 2006
8 Reads

Comparison of CD44 expression in primary tumours and metastases of colorectal cancer.

Oncol Rep. 2006 Oct;16(4):741-6

Oncol Rep

A better understanding on the development of a metastatic phenotype in colorectal cancer (CRC) is essential to help identify patients at high risk for metastasis. Therefore, we have studied the role of the CD44 family of trans-membrane glycoprotein in the process of CRC metastasis, by examining the expression of CD44s and CD44v6 in primary tumours and their metastatic lesions in 46 patients using immunohistochemistry. The expression of both CD44s and CD44v6 was significantly higher (moderate/strong) in primary tumours as compared to their metastases (p=0.008, p=0.0001, respectively). CD44s expression in metastases increased with the degree of the histological grade (p=0.009) and invasiveness of the primary tumour (p=0.002). Disease-free survival (DFS) was shorter in patients who had metastases with a strong/moderate expression of CD44s as compared to those with negative/weak expression (8.3 months vs 16.9 months p=0.221, respectively). Our finding that CD44s expression in metastatic lesions may reflect the aggressiveness of the primary tumour from which it has originated implicates an important link between the two lesions. CD44 expression may also provide valuable biological information as suggested by the observation that up-regulated CD44s expression in metastases is associated with a shorter DFS.

View Article
October 2006
11 Reads

E-cadherin expression pattern in primary colorectal carcinomas and their metastases reflects disease outcome.

World J Gastroenterol 2006 Jul;12(27):4304-9

Department of Oncology and Radiotherapy, Turku University Hospital, Savitehtaankatu 1 PB 52, FIN-20520 Turku, Finland.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087739PMC
http://dx.doi.org/10.3748/wjg.v12.i27.4304DOI Listing
July 2006
8 Reads
14 Citations
2.370 Impact Factor

Thymidylate synthase expression levels: a prognostic and predictive role in advanced colorectal cancer.

Oncol Rep. 2005 Sep;14(3):657-62

Oncol Rep.

Thymidylate synthase (TS) is the rate-limiting enzyme in the synthesis of pyrimidine nucleotides, required for DNA synthesis, and is also a critical target for fluoropyrimidines, which are widely used in the treatment of gastrointestinal tumours. We examined TS expression in tumours from 86 patients with advanced colorectal cancer who received one of two chemotherapy regimes (either irinotecan alone or irinotecan and 5-flurouracil with folinic acid). TS expression was determined immunohistochemically in 86 paraffin-embedded primary tumour sections and assessed using image analysis software. TS was significantly associated with survival, with lower levels of TS expression associated with longer patient survival (p=0.02). Patients with an objective response to treatment had a longer median survival than those who did not show an objective response to treatment (p=0.001). A significant association was found between tumour TS expression and response to treatment with 5-FU plus FA with irinotecan (p=0.05). Sixty-four percent of patients with TS expression levels below the median showed an objective (complete or partial) response to treatment while, 38% with TS expression levels above the median responded. Immunohistochemical TS expression levels might be used both as a prognostic marker and to help identify patients who would benefit from 5-FU based regime.

View Article
September 2005
9 Reads

E-cadherin, CD44s and CD44v6 correlate with tumour differentiation in colorectal cancer.

Oncol Rep. 2005 May;13(5):831-5

Oncol Rep

Cell adhesion molecules (CAMs) are cell surface glycoproteins that are important in cell-cell and cell-matrix interactions and play an important role in cell growth and differentiation. We examined immunohistochemically CD44s, CD44v6 and E-cadherin expression in 86 formalin-fixed, paraffin-embedded primary tumours and 5 metastases. Lower levels of CD44s, CD44v6 and membranous E-cadherin expression were significantly associated with higher tumour grade (p=0.022, p=0.016 and p= 0.041, respectively). Moreover, CD44v6 and membranous E-cadherin expression were correlated with the depth of primary tumour invasion (p=0.030 and p=0.020, respectively), and increased expression of CD44v6 and decreased membranous E-cadherin expression were associated with increased primary tumour invasion. The results suggest that these CAMs are associated with tumour differentiation and invasion in locally advanced and metastatic colorectal carcinoma.

View Article
May 2005
8 Reads

Implementation of DNA cytometric measurements in fine-needle aspiration biopsy diagnostics of breast disease

Cancer. 2004 Dec 25;102(6):380-8.

Cancer

BACKGROUND: For this study, the diagnostic protocol included fine-needle aspiration biopsy (FNAB) and DNA cytometric measurements. The objective of the study was to improve the diagnostic sensitivity of FNAB. METHODS: Sixty-eight FNAB samples were stained using the Feulgen stain, and DNA histograms were produced by selecting the nuclei of cell groups and free cells separately. RESULTS: Among 28 samples that were classified as definitely benign (n = 17 samples) or atypical but benign (n = 11 samples), DNA cytometry generally showed diploid/peridiploid peaks. Three of those samples were associated later with carcinoma. In those samples DNA cytometry did not improve sensitivity. Among moderately atypical samples (n = 17 samples), 8 samples were diagnosed later as carcinoma. DNA cytometry helped the diagnostic procedure in 62.5% of those samples. Among 21 samples that were classified as highly suspicious (n = 10 samples) or definitely malignant (n = 11 samples), DNA cytometry generally showed atypical DNA histograms (20 of 21 histograms), and DNA cytometry supported the diagnosis of carcinoma in 95.2%. Histograms that were based on free cells frequently were more abnormal compared with histograms that were based on cell groups. Histologically verified benign lesions also could show abnormalities in DNA histograms. Accepting wider gates than are used normally for primarily Feulgen stained samples on these restained samples resulted in improved specificity, efficiency, and predictive values. CONCLUSIONS: DNA cytometry has a potential to support the differential diagnosis of breast lesions, and sampling of free cells increases sensitivity. Benign breast lesions (fibrocystic disease, fibroadenoma) included DNA-cytometrically abnormal cell clones and showed tendencies toward polyploidy, which should be included in the diagnostic criteria.

View Article
December 2004
9 Reads

Apocrine change in fine-needle aspiration biopsy: nuclear morphometry and DNA image cytometry.

APMIS. 2003 Sep;111(9):898-904.

APMIS

The aim of this study was to investigate the potential of computerized nuclear morphometry and DNA image cytometry in characterizing the apocrine change of mammary epithelium in fine-needle aspiration biopsy (FNAB). The effect of two different sample processing techniques on the results was also studied. Mean nuclear areas in air-dried smears ranged from 59.0 microm2 to 151.0 microm2 and in ethanol-fixed samples from 32.3 microm2 to 63.4 microm2. The DNA histograms of apocrine cells usually showed a dominant peak in the diploid region. In some cases the mode of the peak was slightly shifted to the right or left in respect to the control peak. One case had a tetraploid cell population, suggesting atypical apocrine change. After histological investigation this case was diagnosed as infiltrating carcinoma. The patient had earlier been treated with x-ray irradiation for a mediastinal lymphoma. Findings of nuclear morphometry and DNA cytometry in apocrine metaplasia are here described in a systematic study for the first time. The data suggest that these methods may help in distinguishing premalignant and malignant apocrine lesions from typical apocrine metaplasia of mammary epithelial cells.

View Article
September 2003
45 Reads

Fine needle aspiration biopsy of the breast. Value of nuclear morphometry after different sampling methods

Anal Quant Cytol Histol. 2003 Apr;25(2):73-80

Anal Quant Cytol Histol

OBJECTIVE: To study the potential of nuclear morphometry in supporting the interpretation of fine needle aspiration biopsy (FNAB) samples of the breast fixed in 50% ethanol and centrifuged on slides. STUDY DESIGN: Computerized morphometry was used to outline the nuclei of breast epithelial cells in breast cancer, fibroadenoma and fibrocystic disease. The diagnoses were histologically confirmed. We applied 2 different sampling methods (measurements done on cell groups and on free cells). RESULTS: The mean nuclear area of cell groups of malignant samples (23) varied from 42 to 125 microns 2, in fibroadenomas from 30 to 50 microns 2 and in fibrocystic disease from 26 to 57 microns 2. The mean nuclear area of free cells varied as follows: cancer, 66-181 microns 2; fibroadenoma, 33-70 microns 2; fibrocystic disease, 35-60 microns 2. Apocrine metaplasia was excluded from comparison on a morphologic basis. CONCLUSION: The study suggests that if the mean nuclear area of cell groups is < 42 microns 2, the lesion is probably benign; if > 57 microns 2, and apocrine metaplasia is excluded, malignancy should be considered. The differential diagnosis between carcinoma and fibroadenoma could be based on free cells: mean area of free cell nuclei < or = 65 microns 2 suggested a benign lesion, and of > or = 71 microns 2 suggested a malignant lesion. Morphometric nuclear size features (exemplified by nuclear area) appeared efficient in distinguishing between malignant and benign lesions when measured from free cells and cell groups.

View Article
April 2003
10 Reads

Prognostication of invasive ductal breast cancer by quantification of E-cadherin immunostaining: the methodology and clinical relevance

Histopathology. 2002 Aug;41(2):127-33.

Histopathology

AIMS: We tried to improve the evaluation of E-cadherin immunostaining in paraffin sections, to distinguish the less aggressive variants of ductal infiltrating breast cancer from other variants. METHODS AND RESULTS: The method graded the membrane staining and estimated the fraction of area of cancer tissue stained at the respective staining grade, resulting in an immunohistochemical staining index. At the cut-point 0.35 the index divided all 157 patients (P=0.0188), and 57 node-positive patients (P= 0.0006) into two groups of different survival. In multivariate analysis (all patients) E-cadherin immunoscore was inferior to mitotic index (SMI) (P=0.0002), but still significant (P=0.0031). Among node-positive patients E-cadherin was even more powerful and superior (P=0.0001) to the still significant SMI (P=0.0023), and E-cadherin immunostaining and the mitotic activity (SMI) combined did not need the support of other prognosticators in the Cox model. CONCLUSIONS: The study suggests that E-cadherin immunostaining can be used efficiently in finding patients with favourable outcome among node-positive patients

View Article
August 2002
12 Reads

Dependence of DNA-histograms on the sampling techniques in fine needle aspirates of the breast.

Anal Cell Pathol. 2002;24(4-5):159-65.

Anal Cell Pathol

48 fine needle aspiration biopsy (FNAB) samples from 25 breast cancer cases, originally used for cytodiagnosis were subjected to DNA cytometry. There were air dried smears stained with the MGG method, and samples stained with HE or PAP stain after 50% ethanol fixation and cytocentrifugation. Different sampling strategies were applied. Four methods were tested: method 1: cell groups measured, method 2: all cells measured, method 3: free cells measured, and method 4: atypical free cells measured. Method 4 showed most often DNA aneuploid histogram patterns, sampling method 1 had the highest number of DNA diploid histogram patterns. Diagnostic approaches may benefit from a sampling method detecting the hiding aneuploid cell population. Grading of neoplasm could potentially benefit from other approaches.

View Article
June 2002
15 Reads